Big-cap biotech Celgene early Thursday beat analysts' third-quarter expectations and raised its EPS outlook, though its best-selling drug faced a few head winds. Celgene (CELG) said sales rose 14% over the year-earlier quarter to $1.42 billion, a hair above analysts' consensus of $1.41 billion. Adjusted earnings rose 26% to $1.29 a share, beating consensus by 2 cents. The company's shares, up 10% for the year, rose a fraction Thursday, closing at